Expanding on Treatment Trends in Platinum-Resistant Ovarian Cancer - Episode 3

PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer

April 3, 2025

Bhavana Pothuri, MD, Tiffany Redfern, MD, FACOG

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on patient-reported outcome data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Current Treatment Approaches and Challenges in Platinum-Resistant Ovarian Cancer

EP. 2: MIRASOL Trial: Final OS Data for Mirvetuximab Soravtansine in FRa+ Platinum-Resistant Ovarian Cancer

Now Viewing

EP. 3: PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer

EP. 4: Exploring Other Potential Roles for Mirvetuximab Soravtansine in Ovarian Cancer

EP. 5: Highlighting Key Ovarian Cancer Data from the 2025 SGO Annual Meeting

EP. 6: Ongoing Research to Watch in Ovarian Cancer in 2025